
|Articles|July 1, 2004
ISTA seeks bromfenac OK; gets nod for injected hyaluronidase
Irvine, CA-ISTA Pharmaceuticals Inc. is seeking FDA approval of its bromfenac sodium ophthalmic solution 0.1% (Xibrom) for the treatment of ocular inflammation following cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
AAO 2025: Which lens to consider in patients with pseudoexfoliation
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5